TOMDF - Todos Medical Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0600
+0.0005 (+0.93%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0595
Open0.0511
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0511 - 0.0700
52 Week Range0.0111 - 0.3400
Volume1,116,578
Avg. Volume2,133,351
Market Cap5.423M
Beta (5Y Monthly)-3.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Todos Medical Enters Into Cross-Distribution Agreement With L1 Systems for Ventilators and COVID Testing

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (MDGS.TA) (MDGS.TA), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution.

  • GlobeNewswire

    Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

    Sub-distributor has network of state and local government clients seeking testing solutions Return to Church program being initiated in Orlando, Fla. area REHOVOT,.

  • GlobeNewswire

    Todos Medical Enters Into Direct Exclusive Distribution Agreement With Gnomegen and Announces US FDA Emergency Use Authorization for its COVID-19 qPCR Test Kits

    ·       Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe ·       Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified.

  • GlobeNewswire

    Todos Medical Announces Positive Data for Serology Point-of-Care Fingerprick Antibody Test Kits

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests for novel coronavirus (COVID-19 or COVID), today announced positive data for its Colloidal Gold point-of-care (POC) 2 to 10 minute fingerprick blood antibody test kits from a study of 71 patients with suspected COVID-19 infection (30 COVID PCR-Positive and 41 COVID PCR-Negative) admitted to the hospital. The data demonstrate that Colloidal Gold accurately distinguishes between COVID positive patients and COVID negative patients, as confirmed by PCR (Quest Labs), with sensitivity of 96.5% using fingerprick blood sample collection and specificity of 97.5% using fingerprick or venous blood sample collection.

  • GlobeNewswire

    Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits

    Gibraltar Brothers & Associates, LLC has entered into agreements with Gnomegen, LLC to supply Todos with its proprietary Real Time digital PCR Test Kits for COVID-19.

  • GlobeNewswire

    Todos Medical Appoints Dr. Lauren Chung to its Board of Directors

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. (TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.

  • GlobeNewswire

    Todos Medical Achieves Medical Importer Status with US FDA

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 15, 2020 -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the.

  • GlobeNewswire

    Todos Medical Provides Corporate Update

    REHOVOT, ISRAEL, SINGAPORE and NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc. Through our entities and teams in the U.S., Israel and Singapore, we are working through the various regulatory and international import/export requirements in order to initiate sales in the United States and abroad.

  • GlobeNewswire

    Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar

    Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee,.

  • Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits
    PR Newswire

    Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits

    Emerald Organic Products, Inc. (OTC: EMOR) and Todos Medical Ltd. (OTCQB: TOMDF) today announced the creation of Corona Diagnostics, LLC, a joint venture partnership formed to address the much-needed demand for COVID-19 screening and diagnostic testing in the United States. The joint venture will be owned 51% by Emerald and 49% by Todos.

  • GlobeNewswire

    Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar

    REHOVOT, Israel and NEW YORK, NY, March 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. (TOMDF), a pre-commercial stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into an exclusive distribution agreement for the United States and Israel (the “Distribution Agreement”) with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (“Shanghai”), for its proprietary colloidal gold immunochromatography test (“Colloidal Gold”).

  • GlobeNewswire

    Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel

    REHOVOT, Israel and New York, NY, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the US and Israel of 3DMed’s ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2  & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). 3DMed’s COVID, COVID/Flu and 3D Machine have received a CE Mark in Europe.

  • GlobeNewswire

    UPDATE: Todos Medical Enters Into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement With 3D BioMed

    REHOVOT, Israel and New York, NY, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3D Biomedicine Science & Technology Co., a China-based cancer precision medicine company, for distribution in the US and Israel of 3D BioMed’s 3DMed 2019-nCoV Detection Kit (COVID), 3DMed 2019-nCoV & Flu A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). 3D BioMed’s COVID, COVID/Flu and 3D Machine have received approval from the Chinese FDA and have received a CE Mark in Europe.

  • GlobeNewswire

    Todos Medical Announces Publication Demonstrating Potential of FTIR Platform to Identify Bacterial and Viral Infections

    Todos Medical Ltd. (TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced the publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled “Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis”. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples yields a differential diagnosis when seeking to make a clinical diagnosis between patients with viral infections, bacterial infections and healthy controls.

  • GlobeNewswire

    Todos Medical Announces Legacy Convertible Note Extension, Lock-Up Agreements, and New Debt Financing

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into convertible note extension agreements and lock-up agreements with certain institutional investors who participated in the Company’s previously announced $1.35M financing round in Q1 2019 (the ‘2019 Bridge Financing’). All remaining investors who participated in the 2019 Bridge Financing have agreed to extend the maturity of those notes until mid-August 2020 and have entered into lock-up agreements with the Company that preclude them from selling common shares in the market until mid-August 2020. A new institutional investor purchased $295,000 in convertible notes from certain institutional investors who participated in the 2019 Financing in order to help facilitate the transaction.

  • GlobeNewswire

    Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos’ proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs). “We are very pleased to see the expansion of the Todos intellectual property portfolio in Europe where Todos is currently in the midst of a pre-commercialization study with partner Orot+ (a division of Orot Luces) for our TM-B1 and TM-B2 breast cancer blood tests,” said Gerald E. Commissiong, President & CEO of Todos Medical.

  • GlobeNewswire

    Todos Medical Releases Letter to Shareholders

    Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study with a view towards obtaining our own CPT code to allow for value-based, consistent reimbursement of an actionable blood test for breast cancer. Please find here a link to the Company’s updated corporate presentation: http://investor.todosmedical.com/static-files/815190c5-2c1f-4e21-9309-dd5aab5802d1 .

  • GlobeNewswire

    Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into an exclusive option agreement to acquire Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab in Alpharetta, Georgia, developing and commercializing the proprietary Videssa® blood test for breast cancer. Videssa has been clinically validated for the early and accurate detection of breast cancer based on data from over one thousand patient samples. “The Videssa technology platform and the menu of cancer and autoantibodies tests from Provista Diagnostics represent a robust, reliable, cost- effective and clinically useful line of products for the early and accurate detection of breast cancer,” said Dr. Jorge Leon, Senior Medical Advisor of Todos.

  • GlobeNewswire

    Todos To Present At Upcoming 12th Annual LD Micro Main Event

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that Todos Medical will be presenting at the upcoming LD Micro International Annual Invitational on Tuesday, December 10th, in Bel-Air, California. Additionally, this event presents an opportunity for Todos Medical to present its value proposition to investors, industry executives and analysts who are interested specifically in the micro-cap space. All interested parties wishing to set up a one-on-one meeting with Todos management are welcome to contact us.

  • Market Exclusive

    Market Morning: Alibaba Goes Hong Kong, Uber Dump, Alzheimer’s Hope, Cannabis Collapse

    Alibaba, Now May Not Be the Best Time to IPO in Hong Kong Alibaba (NYSE:BABA) is going public in Hong Kong with a $13.4 billion listing, and it’s putting extra stress on the Hong Kong banking system specifically at a time when the island is on the verge of exploding in cacophonous riots leading to […]The post Market Morning: Alibaba Goes Hong Kong, Uber Dump, Alzheimer's Hope, Cannabis Collapse appeared first on Market Exclusive.

  • GlobeNewswire

    Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET

    Topline results are expected before the end of the first quarter of 2020. Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimer’s disease, as confirmed with amyloid PET neuroimaging and other Alzheimer’s disease biomarkers.

  • GlobeNewswire

    Todos Medical to Present at Dawson James Small Cap Growth Conference

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that Company management will present at the Dawson James Small Cap Growth Conference on Tuesday, October 29, 2019 beginning at 3:15 P.M. Eastern time. Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis.

  • Market Exclusive

    Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests

    British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.

  • GlobeNewswire

    Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Orot+, the operational division of Orot-Luces (http://orot-luces.com), that executed a distribution agreement with Todos for the commercial distribution of Todos’ TM-B1and TM-B2 blood screening tests for breast cancer, today announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe. The pre-commercial launch study is expected to last approximately 6 months.

  • GlobeNewswire

    Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into a binding term sheet with HWH World Pte Ltd. (“HWH World”), a wholly-owned subsidiary of Singapore eDevelopment (40V.SI) for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada. HWH World is a marketing firm that focuses on health and wellness.